|
|
News Breaks | | | | September 12, 2012 | | 07:40 EDT |  | SNSS | Sunesis Pharmaceuticals price target raised to $7 from $5 at RBC Capital
RBC Capital raised its target on Sunesis as the firm believes that the DSMB’s decision to allow the ongoing Phase III VALOR study for vosaroxin to continue with the addition of 225 patients reflects positively on the drug's risk-benefit profile. The firm expects the study to generate positive data and it maintains an Outperform rating. | |
|
News For SNSS From The Last 14 Days Check below for free stories on SNSS the last two weeks. |
|
|
| May 9, 2013 | | 07:22 EDT |  | SNSS | Sunesis reports Q1 EPS (23c), consensus (20c)
Reports Q1 revenue $1.99M, consensus $750K. | |
|
|
|
|
|
|
